A Phase 3 interventional study of Ruxolitinib and Extracorporeal photopheresis (ECP) in Graft-versus-host Disease (GVHD), sponsored by Incyte Corporation. Completed at 191 sites in 31 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2025-08-12.
Sponsored by Incyte Corporation · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing ruxolitinib in Graft vs Host Disease — 13 open to participants now, 16 under way, 2 of them phase 3. ruxolitinib · Graft vs Host Disease.
Among the 27 studies testing ruxolitinib in Graft vs Host Disease, this one is the 3rd largest by enrollment, is one of 2 that started in 2017, is one of 3 in phase 3, and was the 5th registered.
804 studies on the registry are indexed under Graft vs Host Disease; 149 are open to participants now.
Browse Graft vs Host Disease studies →13 of the 27 studies testing ruxolitinib in Graft vs Host Disease are open now, in 12 countries. Recruiting first, the newest first:
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Ohio State University Comprehensive Cancer Center · Sites in United States
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Bambino Gesù Hospital and Research Institute · Sites in Austria, Czechia, Denmark and 6 more countries
Ages 3 mo–25 yrs
Novartis Pharmaceuticals · Sites in China
Ages 12–100
By country, each count listing its studies:
ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 103 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 42 (41%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 17 · Phase 3 4 · Phase 4 3
First in 2015; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 330 is above the median of 35 across 639 interventional studies indexed under Graft vs Host Disease.
Median enrollment 54 across the 27 interventional studies. Of the 11 that completed or were terminated, 7 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 27 have an industry lead sponsor. The 10 most frequent:
Incyte Corporation is the lead sponsor of 288 studies on the registry; 34 are open to participants now.
Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.
12 studies in Graft vs Host Disease by Incyte Corporation: 1 open now, 1 under way, 1 of them phase 3. Of 8 finished, 5 (63%) have results posted.
Among the 12 studies in Graft vs Host Disease by Incyte Corporation, this one is one of 2 that started in 2017, is one of 3 in phase 3, and was the 3rd registered.
Incyte Corporation’s Graft vs Host Disease studies by the year they started, since 2015.
6 of the studies testing ruxolitinib in Graft vs Host Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07238712St. Petersburg State Pavlov Medical UniversityOptimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor | 2026-12-10 |
| NCT06936566John LevineMAGIC Ruxolitinib for aGVHD | 2027-06-01 |
| NCT06008808Washington University School of MedicineRuxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation | 2027-09-08 |
| NCT07796620Peking University People's HospitalSirolimus+Ruxolitinib+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to CNI | 2027-09-30 |
| NCT07356245Ohio State University Comprehensive Cancer CenterRuxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma | 2027-10-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 27 studies testing ruxolitinib in Graft vs Host Disease, from their registry updates:
Among Incyte Corporation’s 12 in Graft vs Host Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the efficacy of ruxolitinib against best available therapy in participants with steroid-refractory chronic graft-versus-host disease (SR cGvHD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants with clinically diagnosed moderate to severe cGvHD according to NIH Consensus Criteria prior to randomization:
Participants currently receiving systemic or topical for the treatment of cGvHD for a duration of \< 12 months prior to Cycle 1 Day 1 (if applicable), and have a confirmed diagnosis of steroid- cGvHD defined per 2014 NIH consensus criteria irrespective of the concomitant use of a calcineurin inhibitor (CNI), as follows:
Exclusion Criteria:
Patients that transition from active aGvHD to cGvHD without tapering off corticosteroids ± CNI and any systemic treatment
* Patients receiving up to 30 mg by mouth once a day of hydrocortisone (i.e., physiologic replacement dose) of corticosteroids are allowed.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ruxolitinib for the treatment period and extension period.
Drug: Ruxolitinib
Best available therapy for the treatment period and extension period, with optional crossover to ruxolitinib after Cycle 6.
Drug: Extracorporeal photopheresis (ECP) · Drug: Low-dose methotrexate (MTX) · Drug: Mycophenolate mofetil (MMF) · Drug: mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus) · Drug: Infliximab · Drug: Rituximab · Drug: Pentostatin · Drug: Imatinib · Drug: Ibrutinib
Ruxolitinib twice daily at the protocol-defined starting dose.
Also known as: Jakafi, INCB018424
Best available therapy (BAT) will be selected by the investigator for each participant. BAT may not include experimental agents (ie, those not approved for the treatment of any indication) as well as a limited number of other selected drugs in accordance with the protocol-defined requirements. The BAT in this study will be among the following treatments currently used in this setting (no other types or combinations of BATs are permitted in this study).
Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
Efficacy of Ruxolitinib Versus Investigator's Choice Best Available Therapy (BAT) in Participants With Moderate or Severe Steroid Refractory Chronic Graft Versus Host Disease (SR-cGvHD) Assessed by Overall Response Rate (ORR) at the Cycle 7 Day 1 Visit
ORR was defined as the percentage of participants in each arm demonstrating a complete response (CR) or partial response (PR) based on chronic GvHD (cGvHD) disease assessments (National Institutes of Health Consensus Criteria) without the requirement of additional systemic therapies for an earlier progression, mixed response, or non-response. Scoring of response was relative to the organ score at the time of randomization. CR: complete resolution of all signs and symptoms of cGVHD in all evaluable organs without the initiation or addition of new systemic therapy. PR: improvement in at least one organ (e.g., improvement of 1 or more points on a 4- to 7-point scale, or an improvement of 2 or more points on a 10- to 12-point scale) without progression in other organs or sites, initiation, or addition of new systemic therapies.
Time frame: Cycle 7 Day 1 (each cycle was comprised of 4 weeks)
Rate of Participants With Clinically Relevant Improvement of the Modified Lee cGvHD Symptom Scale Score
To assess improvement of symptoms based on the total symptom score (TSS); a responder was defined as having achieved a clinically relevant reduction from Baseline of the TSS. The scale consists of 30 items in 7 subscales (skin, eye, mouth, lung, nutrition, energy, and psychological). Participants reported their level of symptom "bother" over the previous month on a 5-point likert scale: not at all, slightly, moderately, quite a bit, or extremely. Subscale scores and the summary score range from 0 to 100, with a higher score indicating worse symptoms.
Time frame: Baseline; Cycle 7 Day 1 (each cycle was comprised of 4 weeks)
Rate of Failure-free Survival (FFS)
Composite time to event endpoint incorporating the following FFS events: (i) relapse or recurrence of underlying disease or death due to underlying disease, (ii) nonrelapse mortality, or (iii) addition or initiation of another systemic therapy for cGvHD.
Time frame: Baseline to when the last participant reached Cycle 7 Day 1 (each cycle was comprised of 4 weeks)
Rate of FFS at Study Completion
Composite time to event endpoint incorporating the following FFS events: (i) relapse or recurrence of underlying disease or death due to underlying disease, (ii) nonrelapse mortality, or (iii) addition or initiation of another systemic therapy for cGvHD.
Time frame: From Baseline to Last Participant Last Visit (LPLV) (approximately 5 years)
Best Overall Response (BOR) at Cycle 7 Day 1
BOR was defined as the percentage of participants who achieved an overall response (CR+PR) based on cGvHD disease assessments (National Institutes of Health Consensus Criteria) without the requirement of additional systemic therapies for an earlier progression, mixed response, or non-response at any time point (up to Cycle 7 Day 1 or the start of additional systemic therapy for cGvHD). Scoring of response was relative to the organ score at the time of randomization. CR: complete resolution of all signs and symptoms of cGVHD in all evaluable organs without the initiation or addition of new systemic therapy. PR: improvement in at least one organ (e.g., improvement of 1 or more points on a 4- to 7-point scale, or an improvement of 2 or more points on a 10- to 12-point scale) without progression in other organs or sites, initiation, or addition of new systemic therapies. This analysis was based on the primary cutoff date (May 2020).
Time frame: up to Cycle 7 Day 1 (each cycle was comprised of 4 weeks)
BOR During Cross-over Treatment With Ruxolitinib
BOR was defined as the percentage of participants who achieved an overall response (CR+PR) based on cGvHD disease assessments (National Institutes of Health Consensus Criteria) without the requirement of additional systemic therapies for an earlier progression, mixed response, or non-response at any time point (up to Cycle 7 Day 1 or the start of additional systemic therapy for cGvHD). Scoring of response was relative to the organ score at the time of randomization. CR: complete resolution of all signs and symptoms of cGVHD in all evaluable organs without the initiation or addition of new systemic therapy. PR: improvement in at least one organ (e.g., improvement of 1 or more points on a 4- to 7-point scale, or an improvement of 2 or more points on a 10- to 12-point scale) without progression in other organs or sites, initiation, or addition of new systemic therapies.
Time frame: from Crossover Cycle 1 Day 1 to any time point up to and including Crossover Cycle 7 Day 1 (each cycle was comprised of 4 weeks)
ORR at the End of Cycle 3
ORR was defined as the percentage of participants in each arm demonstrating a CR or PR based on cGvHD disease assessments (National Institutes of Health Consensus Criteria) without the requirement of additional systemic therapies for an earlier progression, mixed response, or non-response. Scoring of response was relative to the organ score at the time of randomization. CR: complete resolution of all signs and symptoms of cGVHD in all evaluable organs without the initiation or addition of new systemic therapy. PR: improvement in at least one organ (e.g., improvement of 1 or more points on a 4- to 7-point scale, or an improvement of 2 or more points on a 10- to 12-point scale) without progression in other organs or sites, initiation, or addition of new systemic therapies.
Time frame: Cycle 4 Day 1 (each cycle was comprised of 4 weeks)
Duration of Response Through Study Completion
DOR was defined as the time from first response until cGvHD progression, death, or the date of change/addition of systemic therapies for cGvHD and as assessed for responders only. Response was based on cGvHD disease assessments (National Institutes of Health consensus criteria). Duration of response was evaluated in participants who achieved a CR or PR at or before Cycle 7 Day 1. The analysis included a larger number of participants than the number of participants who achieved CR or PR at Cycle 7 Day 1 (82 ruxolitinib and 42 BAT) because the analysis took into account not only those participants who achieved CR or PR at Cycle 7 Day 1, but also participants who achieved CR or PR before Cycle 7 Day 1 but who may have lost their response at Cycle 7 Day 1. For this reason, the number of participants in this analysis does not align with the best overall response (BOR) at Cycle 7 Day 1. This analysis was based on the cutoff date upon study completion (December 2022).
Time frame: from first response to LPLV (approximately 5 years)
Overall Survival (OS)
Overall survival was defined as the time from the date of randomization to the date of death due to any cause.
Time frame: from the date of randomization to the date of death due to any cause up to LPLV (approximately 5 years)
Cumulative Incidence of Non-relapse Mortality (NRM)
Defined as the cumulative incidence rate from competing risk analysis for NRM from the date of randomization to the date of death not preceded by underlying disease relapse/recurrence.
Time frame: Months 3, 6, 12, 18, 24, 30, and 36
Percentage of Participants With a ≥ 50% Reduction in Daily Corticosteroid Dose
All corticosteroid dosages prescribed to the participant and all dose changes during the study were to be recorded for assessment of participants with a ≥ 50% reduction in daily corticosteroid dose.
Time frame: from Day 15 up to Day 182
Percentage of Participants Successfully Tapered Off of All Corticosteroids
All corticosteroid dosages prescribed to the participant and all dose changes during the study were to be recorded for assessment of participants who successfully tapered off of all corticosteroids. Participants who completely tapered off corticosteroids refer to those who permanently discontinued steroids as per the dose administration panel and who did not restart steroids in the same interval. Participants who were tapered off and continued follow-up were also counted as being tapered off with 0 dose in subsequent intervals until they discontinued from the main treatment period or restarted steroid treatment.
Time frame: up to Day 179
Cumulative Incidence of Malignancy Relapse/Recurrence (MR)
Defined as the cumulative incidence rate from competing risk analysis of MR from the date of randomization to hematologic malignancy relapse/recurrence.
Time frame: Months 3, 6, 12, 18, 24, 30, and 36
Change From Baseline in Functional Assessment of Cancer Therapy - Bone Marrow Transplantation (FACT-BMT)
Change from Baseline was calculated as the post-Baseline value minus the Baseline value. The FACT-BMT is a 50-item self-report questionnaire that measures the effect of a therapy on domains including physical, functional, social/family, and emotional well-being, together with additional concerns relevant for bone marrow transplantation participants. The questions were based on a 5-point Likert scale, where 0 corresponds to "not at all" and 4 corresponds to "very much." The higher the final score, the better the quality of life. The FACT-BMT total score ranges from 0 to 148.
Time frame: Baseline; up to Cycle 39 Day 1 (each cycle was comprised of 4 weeks)
Change From Baseline in EQ-5D-5L
The EQ-5D-5L is a descriptive classification consisting of five dimensions of health: mobility, self-care, usual activities, anxiety/depression, and pain/discomfort. The five-level version (no problems, slight problems, moderate problems, severe problems, and extreme problems) uses a 5-point Likert scale, with 1 being no problems and 5 being extreme problems.
Time frame: Baseline; up to Cycle 39 Day 1 (each cycle was comprised of 4 weeks)
Number of Participants With Any Treatment-emergent Adverse Event (TEAE)
Adverse events were defined as the appearance of (or worsening of any pre-existing) undesirable signs, symptoms, or medical conditions that occurred after the participant's signed informed consent was obtained. Abnormal laboratory values or test results occurring after informed consent constituted adverse events only if they induced clinical signs or symptoms, were considered clinically significant, required therapy (e.g., hematologic abnormality that required transfusion or hematological stem cell support), or required changes in study medication(s). TEAEs were defined as those AEs that started or worsened during the on-treatment period (either randomized or cross-over period).
Time frame: from Baseline to LPLV (approximately 5 years)
Cmax of Ruxolitinib After Single (Cycle 1 Day 1) and Multiple (Cycle 1 Day 15) Doses
Cmax was defined as the maximum observed plasma concentration of ruxolitinib. Early enrolling participants (approximately the first 8 adult and first 4 adolescent participants) randomized to ruxolitinib arm followed an "extensive PK" sampling schedule. Subsequent participants randomized to ruxolitinib, any randomized participants receiving ruxolitinib after Cycle 6, and any randomized participants receiving BAT that cross over to ruxolitinib followed the "sparse PK" sampling schedule.
Time frame: Extensive Sampling Schedule: Cycle 1 Days 1 and 15: predose; 0.5, 1, 1.5, 4, 6, and 9 hours post-dose. Sparse Sampling Schedule: Cycle 1 Days 1 and 15: predose; 1.5 hours post-dose
AUClast of Ruxolitinib After Single (Cycle 1 Day 1) and Multiple (Cycle 1 Day 15) Doses
AUClast was defined as the area under the concentration-time curve up to the last measurable concentration of ruxolitinib. Early enrolling participants (approximately the first 8 adult and first 4 adolescent participants) randomized to ruxolitinib arm followed an "extensive PK" sampling schedule. Subsequent participants randomized to ruxolitinib, any randomized participants receiving ruxolitinib after Cycle 6, and any randomized participants receiving BAT that cross over to ruxolitinib followed the "sparse PK" sampling schedule.
Time frame: Extensive Sampling Schedule: Cycle 1 Days 1 and 15: predose; 0.5, 1, 1.5, 4, 6, and 9 hours post-dose. Sparse Sampling Schedule: Cycle 1 Days 1 and 15: predose; 1.5 hours post-dose
AUCinf of Ruxolitinib After Single (Cycle 1 Day 1) and Multiple (Cycle 1 Day 15) Doses
AUCinf was defined as the area under the concentration-time curve from time 0 to infinity. Early enrolling participants (approximately the first 8 adult and first 4 adolescent participants) randomized to ruxolitinib arm followed an "extensive PK" sampling schedule. Subsequent participants randomized to ruxolitinib, any randomized participants receiving ruxolitinib after Cycle 6, and any randomized participants receiving BAT that cross over to ruxolitinib followed the "sparse PK" sampling schedule.
Time frame: Extensive Sampling Schedule: Cycle 1 Days 1 and 15: predose; 0.5, 1, 1.5, 4, 6, and 9 hours post-dose. Sparse Sampling Schedule: Cycle 1 Days 1 and 15: predose; 1.5 hours post-dose
CL/F of Ruxolitinib After Single (Cycle 1 Day 1) and Multiple (Cycle 1 Day 15) Doses
CL/F was defined as the oral dose clearance of ruxolitinib. Early enrolling participants (approximately the first 8 adult and first 4 adolescent participants) randomized to ruxolitinib arm followed an "extensive PK" sampling schedule. Subsequent participants randomized to ruxolitinib, any randomized participants receiving ruxolitinib after Cycle 6, and any randomized participants receiving BAT that cross over to ruxolitinib followed the "sparse PK" sampling schedule.
Time frame: Extensive Sampling Schedule: Cycle 1 Days 1 and 15: predose; 0.5, 1, 1.5, 4, 6, and 9 hours post-dose. Sparse Sampling Schedule: Cycle 1 Days 1 and 15: predose; 1.5 hours post-dose
Vz/F of Ruxolitinib After Single (Cycle 1 Day 1) and Multiple (Cycle 1 Day 15) Doses
Vz/F was defined as the apparent oral dose volume of distribution of ruxolitinib. Early enrolling participants (approximately the first 8 adult and first 4 adolescent participants) randomized to ruxolitinib arm followed an "extensive PK" sampling schedule. Subsequent participants randomized to ruxolitinib, any randomized participants receiving ruxolitinib after Cycle 6, and any randomized participants receiving BAT that cross over to ruxolitinib followed the "sparse PK" sampling schedule.
Time frame: Extensive Sampling Schedule: Cycle 1 Days 1 and 15: predose; 0.5, 1, 1.5, 4, 6, and 9 hours post-dose. Sparse Sampling Schedule: Cycle 1 Days 1 and 15: predose; 1.5 hours post-dose
Tmax of Ruxolitinib After Single (Cycle 1 Day 1) and Multiple (Cycle 1 Day 15) Doses
tmax was defined as the time to reach the maximum plasma concentration of ruxolitinib. Early enrolling participants (approximately the first 8 adult and first 4 adolescent participants) randomized to ruxolitinib arm followed an "extensive PK" sampling schedule. Subsequent participants randomized to ruxolitinib, any randomized participants receiving ruxolitinib after Cycle 6, and any randomized participants receiving BAT that cross over to ruxolitinib followed the "sparse PK" sampling schedule.
Time frame: Extensive Sampling Schedule: Cycle 1 Days 1 and 15: predose; 0.5, 1, 1.5, 4, 6, and 9 hours post-dose. Sparse Sampling Schedule: Cycle 1 Days 1 and 15: predose; 1.5 hours post-dose
t1/2 of Ruxolitinib After Single (Cycle 1 Day 1) and Multiple (Cycle 1 Day 15) Doses
t1/2 was defined as the apparent terminal phase disposition half-life of ruxolitinib. Early enrolling participants (approximately the first 8 adult and first 4 adolescent participants) randomized to ruxolitinib arm followed an "extensive PK" sampling schedule. Subsequent participants randomized to ruxolitinib, any randomized participants receiving ruxolitinib after Cycle 6, and any randomized participants receiving BAT that cross over to ruxolitinib followed the "sparse PK" sampling schedule.
Time frame: Extensive Sampling Schedule: Cycle 1 Days 1 and 15: predose; 0.5, 1, 1.5, 4, 6, and 9 hours post-dose. Sparse Sampling Schedule: Cycle 1 Days 1 and 15: predose; 1.5 hours post-dose
Utilization of Medical Resources
The percentage of participants with at least one submission to healthcare encounter was assessed.
Time frame: from Baseline to LPLV (approximately 5 years)
The study was conducted in 29 countries globally. During the main treatment period, participants were randomly assigned to a ruxolitinib arm or a Best Available Therapy (BAT) arm for 6 cycles of treatment. At the end of Cycle 6, participants in the BAT arm either crossed over to ruxolitinib treatment or entered the survival follow-up phase.
| Milestone | Ruxolitinib | Best Available Therapy | Ruxolitinib Cross-Over Period |
|---|---|---|---|
| Started | 165 | 164 | 0 |
| Completed | 29 | 24 | 0 |
| Not completed | 136 | 140 | 0 |
| Withdrew: Lost to follow-up | 3 | 0 | 0 |
| Withdrew: Participant/guardian decision | 7 | 14 | 0 |
| Withdrew: Physician decision | 43 | 18 | 0 |
| Withdrew: Failure to meet protocol continuation criteria | 4 | 5 | 0 |
| Withdrew: Death | 10 | 7 | 0 |
| Withdrew: Disease relapse | 12 | 7 | 0 |
| Withdrew: Lack of efficacy | 25 | 77 | 0 |
| Withdrew: Adverse event | 32 | 12 | 0 |
| Milestone | Ruxolitinib | Best Available Therapy | Ruxolitinib Cross-Over Period |
|---|---|---|---|
| Started | 0 | 0 | 70 |
| Completed | 0 | 0 | 16 |
| Not completed | 0 | 0 | 54 |
| Withdrew: Death | 0 | 0 | 2 |
| Withdrew: Participant/guardian decision | 0 | 0 | 7 |
| Withdrew: Physician decision | 0 | 0 | 29 |
| Withdrew: Lack of efficacy | 0 | 0 | 8 |
| Withdrew: Adverse event | 0 | 0 | 6 |
| Withdrew: Disease relapse | 0 | 0 | 2 |
ORR was defined as the percentage of participants in each arm demonstrating a complete response (CR) or partial response (PR) based on chronic GvHD (cGvHD) disease assessments (National Institutes of Health Consensus Criteria) without the requirement of additional systemic therapies for an earlier progression, mixed response, or non-response. Scoring of response was relative to the organ score at the time of randomization. CR: complete resolution of all signs and symptoms of cGVHD in all evaluable organs without the initiation or addition of new systemic therapy. PR: improvement in at least one organ (e.g., improvement of 1 or more points on a 4- to 7-point scale, or an improvement of 2 or more points on a 10- to 12-point scale) without progression in other organs or sites, initiation, or addition of new systemic therapies.
| percentage of participants | Ruxolitinib | Best Available Therapy |
|---|---|---|
| Efficacy of Ruxolitinib Versus Investigator's Choice Best Available Therapy (BAT) in Participants With Moderate or Severe Steroid Refractory Chronic Graft Versus Host Disease (SR-cGvHD) Assessed by Overall Response Rate (ORR) at the Cycle 7 Day 1 Visit | 49.7 (41.8 to 57.6) | 25.6 (19.1 to 33.0) |
To assess improvement of symptoms based on the total symptom score (TSS); a responder was defined as having achieved a clinically relevant reduction from Baseline of the TSS. The scale consists of 30 items in 7 subscales (skin, eye, mouth, lung, nutrition, energy, and psychological). Participants reported their level of symptom "bother" over the previous month on a 5-point likert scale: not at all, slightly, moderately, quite a bit, or extremely. Subscale scores and the summary score range from 0 to 100, with a higher score indicating worse symptoms.
| percentage of participants | Ruxolitinib | Best Available Therapy |
|---|---|---|
| Rate of Participants With Clinically Relevant Improvement of the Modified Lee cGvHD Symptom Scale Score | 24.2 (17.9 to 31.5) | 11.0 (6.6 to 16.8) |
Composite time to event endpoint incorporating the following FFS events: (i) relapse or recurrence of underlying disease or death due to underlying disease, (ii) nonrelapse mortality, or (iii) addition or initiation of another systemic therapy for cGvHD.
| months | Ruxolitinib | Best Available Therapy |
|---|---|---|
| Rate of Failure-free Survival (FFS) | NA (18.6 to NA) | 5.7 (5.6 to 6.5) |
Composite time to event endpoint incorporating the following FFS events: (i) relapse or recurrence of underlying disease or death due to underlying disease, (ii) nonrelapse mortality, or (iii) addition or initiation of another systemic therapy for cGvHD.
| months | Ruxolitinib | Best Available Therapy |
|---|---|---|
| Rate of FFS at Study Completion | 38.4 (22.1 to NA) | 5.7 (5.6 to 6.5) |
BOR was defined as the percentage of participants who achieved an overall response (CR+PR) based on cGvHD disease assessments (National Institutes of Health Consensus Criteria) without the requirement of additional systemic therapies for an earlier progression, mixed response, or non-response at any time point (up to Cycle 7 Day 1 or the start of additional systemic therapy for cGvHD). Scoring of response was relative to the organ score at the time of randomization. CR: complete resolution of all signs and symptoms of cGVHD in all evaluable organs without the initiation or addition of new systemic therapy. PR: improvement in at least one organ (e.g., improvement of 1 or more points on a 4- to 7-point scale, or an improvement of 2 or more points on a 10- to 12-point scale) without progression in other organs or sites, initiation, or addition of new systemic therapies. This analysis was based on the primary cutoff date (May 2020).
| percentage of participants | Ruxolitinib | Best Available Therapy |
|---|---|---|
| Best Overall Response (BOR) at Cycle 7 Day 1 | 76.4 (69.1 to 82.6) | 60.4 (52.4 to 67.9) |
BOR was defined as the percentage of participants who achieved an overall response (CR+PR) based on cGvHD disease assessments (National Institutes of Health Consensus Criteria) without the requirement of additional systemic therapies for an earlier progression, mixed response, or non-response at any time point (up to Cycle 7 Day 1 or the start of additional systemic therapy for cGvHD). Scoring of response was relative to the organ score at the time of randomization. CR: complete resolution of all signs and symptoms of cGVHD in all evaluable organs without the initiation or addition of new systemic therapy. PR: improvement in at least one organ (e.g., improvement of 1 or more points on a 4- to 7-point scale, or an improvement of 2 or more points on a 10- to 12-point scale) without progression in other organs or sites, initiation, or addition of new systemic therapies.
| percentage of participants | Ruxolitinib Cross-Over Period |
|---|---|
| BOR During Cross-over Treatment With Ruxolitinib | 81.4 (70.3 to 89.7) |
ORR was defined as the percentage of participants in each arm demonstrating a CR or PR based on cGvHD disease assessments (National Institutes of Health Consensus Criteria) without the requirement of additional systemic therapies for an earlier progression, mixed response, or non-response. Scoring of response was relative to the organ score at the time of randomization. CR: complete resolution of all signs and symptoms of cGVHD in all evaluable organs without the initiation or addition of new systemic therapy. PR: improvement in at least one organ (e.g., improvement of 1 or more points on a 4- to 7-point scale, or an improvement of 2 or more points on a 10- to 12-point scale) without progression in other organs or sites, initiation, or addition of new systemic therapies.
| percentage of participants | Ruxolitinib | Best Available Therapy |
|---|---|---|
| ORR at the End of Cycle 3 | 54.5 (46.6 to 62.3) | 31.1 (24.1 to 38.8) |
DOR was defined as the time from first response until cGvHD progression, death, or the date of change/addition of systemic therapies for cGvHD and as assessed for responders only. Response was based on cGvHD disease assessments (National Institutes of Health consensus criteria). Duration of response was evaluated in participants who achieved a CR or PR at or before Cycle 7 Day 1. The analysis included a larger number of participants than the number of participants who achieved CR or PR at Cycle 7 Day 1 (82 ruxolitinib and 42 BAT) because the analysis took into account not only those participants who achieved CR or PR at Cycle 7 Day 1, but also participants who achieved CR or PR before Cycle 7 Day 1 but who may have lost their response at Cycle 7 Day 1. For this reason, the number of participants in this analysis does not align with the best overall response (BOR) at Cycle 7 Day 1. This analysis was based on the cutoff date upon study completion (December 2022).
| Months | Ruxolitinib | Best Available Therapy |
|---|---|---|
| Duration of Response Through Study Completion | NA (NA to NA) | 6.4 (4.9 to 11.4) |
Overall survival was defined as the time from the date of randomization to the date of death due to any cause.
| months | Ruxolitinib | Best Available Therapy |
|---|---|---|
| Overall Survival (OS) | NA (NA to NA) | NA (41.0 to NA) |
Defined as the cumulative incidence rate from competing risk analysis for NRM from the date of randomization to the date of death not preceded by underlying disease relapse/recurrence.
| percentage of participants | Ruxolitinib | Best Available Therapy |
|---|---|---|
| Month 3 | 5.45 (2.68 to 9.67) | 4.44 (1.96 to 8.48) |
| Month 6 | 9.13 (5.34 to 14.15) | 6.43 (3.28 to 11.03) |
| Month 12 | 15.30 (10.26 to 21.26) | 15.12 (9.94 to 21.30) |
| Month 18 | 15.93 (10.78 to 21.98) | 16.48 (11.06 to 22.84) |
| Month 24 | 17.83 (12.37 to 24.10) | 19.22 (13.36 to 25.90) |
| Month 30 | 17.83 (12.37 to 24.10) | 19.22 (13.94 to 26.67) |
| Month 36 | 17.83 (12.37 to 24.10) | 22.0 (15.73 to 28.96) |
All corticosteroid dosages prescribed to the participant and all dose changes during the study were to be recorded for assessment of participants with a ≥ 50% reduction in daily corticosteroid dose.
| percentage of participants | Ruxolitinib | Best Available Therapy |
|---|---|---|
| Day 15 to ≤ Day 28 | 12.7 | 13.2 |
| Day 29 to ≤ Day 42 | 35.0 | 33.1 |
| Day 43 to ≤ Day 56 | 48.4 | 41.1 |
| Day 57 to ≤ Day 70 | 58.7 | 47.9 |
| Day 71 to ≤ Day 84 | 62.3 | 51.4 |
| Day 85 to ≤ Day 98 | 69.5 | 54.0 |
| Day 99 to ≤ Day 112 | 71.2 | 60.4 |
| Day 113 to ≤ Day 126 | 73.2 | 66.2 |
| Day 127 to ≤ Day 140 | 72.8 | 68.3 |
| Day 141 to ≤ Day 154 | 70.0 | 68.3 |
| Day 155 to ≤ Day 168 | 74.6 | 71.6 |
| Day 169 to ≤ Day 182 | 81.9 | 88.8 |
All corticosteroid dosages prescribed to the participant and all dose changes during the study were to be recorded for assessment of participants who successfully tapered off of all corticosteroids. Participants who completely tapered off corticosteroids refer to those who permanently discontinued steroids as per the dose administration panel and who did not restart steroids in the same interval. Participants who were tapered off and continued follow-up were also counted as being tapered off with 0 dose in subsequent intervals until they discontinued from the main treatment period or restarted steroid treatment.
| percentage of participants | Ruxolitinib | Best Available Therapy |
|---|---|---|
| Day 1 to ≤ Day 28 | 2.5 | 2.6 |
| Day 29 to ≤ Day 56 | 9.6 | 5.4 |
| Day 57 to ≤ Day 84 | 14.0 | 8.5 |
| Day 85 to ≤ Day 112 | 16.3 | 10.3 |
| Day 113 to ≤ Day 140 | 19.7 | 12.4 |
| Day 141 to ≤ Day 168 | 24.2 | 16.8 |
| Day 169 to ≤ Day 179 | 24.1 | 15.9 |
Defined as the cumulative incidence rate from competing risk analysis of MR from the date of randomization to hematologic malignancy relapse/recurrence.
| percentage of participants | Ruxolitinib | Best Available Therapy |
|---|---|---|
| 0 to < 3 months | 1.92 (0.52 to 5.12) | 1.31 (0.26 to 4.27) |
| 3 to < 6 months | 3.22 (1.20 to 6.93) | 2.65 (0.87 to 6.21) |
| 6 to < 12 months | 5.18 (2.42 to 9.49) | 6.08 (2.98 to 10.73) |
| 12 to < 18 months | 7.82 (4.25 to 12.77) | 6.08 (2.98 to 10.73) |
| 18 to < 24 months | 8.48 (4.74 to 13.57) | 6.08 (2.98 to 10.73) |
| 24 to <30 months | 8.48 (4.74 to 13.57) | 6.78 (3.46 to 11.62) |
| 30 to <36 months | 8.48 (4.74 to 13.57) | 7.50 (3.96 to 12.52) |
Change from Baseline was calculated as the post-Baseline value minus the Baseline value. The FACT-BMT is a 50-item self-report questionnaire that measures the effect of a therapy on domains including physical, functional, social/family, and emotional well-being, together with additional concerns relevant for bone marrow transplantation participants. The questions were based on a 5-point Likert scale, where 0 corresponds to "not at all" and 4 corresponds to "very much." The higher the final score, the better the quality of life. The FACT-BMT total score ranges from 0 to 148.
| scores on a scale | Ruxolitinib | Best Available Therapy |
|---|---|---|
| Cycle 2 Day 1 | 2.32 ± 12.191 | -0.22 ± 14.949 |
| Cycle 3 Day 1 | 0.62 ± 14.452 | -1.82 ± 15.849 |
| Cycle 4 Day 1 | 1.98 ± 15.888 | -1.05 ± 16.147 |
| Cycle 5 Day 1 | 1.25 ± 14.577 | -0.23 ± 18.903 |
| Cycle 6 Day 1 | 2.91 ± 14.562 | 2.41 ± 14.766 |
| Cycle 7 Day 1 | 4.14 ± 14.669 | 0.85 ± 16.811 |
| Cycle 9 Day 1 | 5.32 ± 16.815 | 1.20 ± 17.635 |
| Cycle 12 Day 1 | 7.26 ± 19.296 | 3.74 ± 18.059 |
| Cycle 15 Day 1 | 5.07 ± 18.220 | 7.58 ± 17.063 |
| Cycle 18 Day 1 | 4.10 ± 19.440 | 8.19 ± 17.993 |
| Cycle 21 Day 1 | 5.24 ± 19.485 | 3.68 ± 17.378 |
| Cycle 24 Day 1 | 5.90 ± 19.662 | 7.84 ± 18.561 |
| Cycle 27 Day 1 | 6.23 ± 18.880 | 5.10 ± 18.885 |
| Cycle 30 Day 1 | 7.53 ± 20.314 | 5.75 ± 21.037 |
| Cycle 33 Day 1 | 5.17 ± 20.330 | 5.67 ± 22.573 |
| Cycle 36 Day 1 | 8.72 ± 18.710 | 4.77 ± 24.186 |
| Cycle 39 Day 1 | 8.65 ± 21.669 | 6.64 ± 22.384 |
The EQ-5D-5L is a descriptive classification consisting of five dimensions of health: mobility, self-care, usual activities, anxiety/depression, and pain/discomfort. The five-level version (no problems, slight problems, moderate problems, severe problems, and extreme problems) uses a 5-point Likert scale, with 1 being no problems and 5 being extreme problems.
| scores on a scale | Ruxolitinib | Best Available Therapy |
|---|---|---|
| Cycle 2 Day 1 | 0.03 ± 0.214 | -0.01 ± 0.163 |
| Cycle 3 Day 1 | 0.03 ± 0.221 | -0.04 ± 0.259 |
| Cycle 4 Day 1 | 0.04 ± 0.196 | -0.01 ± 0.192 |
| Cycle 5 Day 1 | 0.02 ± 0.210 | -0.03 ± 0.243 |
| Cycle 6 Day 1 | 0.05 ± 0.230 | 0.01 ± 0.186 |
| Cycle 7 Day 1 | 0.07 ± 0.234 | -0.00 ± 0.225 |
| Cycle 9 Day 1 | 0.07 ± 0.228 | -0.02 ± 0.166 |
| Cycle 12 Day 1 | 0.07 ± 0.187 | 0.02 ± 0.158 |
| Cycle 15 Day 1 | 0.07 ± 0.250 | 0.03 ± 0.140 |
| Cycle 18 Day 1 | 0.07 ± 0.299 | 0.02 ± 0.110 |
| Cycle 21 Day 1 | 0.08 ± 0.268 | -0.00 ± 0.222 |
| Cycle 24 Day 1 | 0.07 ± 0.272 | 0.01 ± 0.164 |
| Cycle 27 Day 1 | 0.06 ± 0.299 | 0.03 ± 0.182 |
| Cycle 30 Day 1 | 0.05 ± 0.261 | 0.01 ± 0.159 |
| Cycle 33 Day 1 | 0.00 ± 0.282 | 0.05 ± 0.186 |
| Cycle 36 Day 1 | 0.06 ± 0.231 | 0.04 ± 0.216 |
| Cycle 39 Day 1 | 0.06 ± 0.255 | 0.01 ± 0.214 |
Adverse events were defined as the appearance of (or worsening of any pre-existing) undesirable signs, symptoms, or medical conditions that occurred after the participant's signed informed consent was obtained. Abnormal laboratory values or test results occurring after informed consent constituted adverse events only if they induced clinical signs or symptoms, were considered clinically significant, required therapy (e.g., hematologic abnormality that required transfusion or hematological stem cell support), or required changes in study medication(s). TEAEs were defined as those AEs that started or worsened during the on-treatment period (either randomized or cross-over period).
| Participants | Ruxolitinib | Best Available Therapy | Ruxolitinib Cross-Over Period |
|---|---|---|---|
| Number of Participants With Any Treatment-emergent Adverse Event (TEAE) | 165 | 148 | 70 |
Cmax was defined as the maximum observed plasma concentration of ruxolitinib. Early enrolling participants (approximately the first 8 adult and first 4 adolescent participants) randomized to ruxolitinib arm followed an "extensive PK" sampling schedule. Subsequent participants randomized to ruxolitinib, any randomized participants receiving ruxolitinib after Cycle 6, and any randomized participants receiving BAT that cross over to ruxolitinib followed the "sparse PK" sampling schedule.
| nanograms per milliliter (ng/mL) | Ruxolitinib |
|---|---|
| Day 1 | 167 ± 39.3 |
| Day 15 | 215 ± 48.8 |
AUClast was defined as the area under the concentration-time curve up to the last measurable concentration of ruxolitinib. Early enrolling participants (approximately the first 8 adult and first 4 adolescent participants) randomized to ruxolitinib arm followed an "extensive PK" sampling schedule. Subsequent participants randomized to ruxolitinib, any randomized participants receiving ruxolitinib after Cycle 6, and any randomized participants receiving BAT that cross over to ruxolitinib followed the "sparse PK" sampling schedule.
| ng*hour/mL | Ruxolitinib |
|---|---|
| Day 1 | 636 ± 40.8 |
| Day 15 | 945 ± 56.1 |
AUCinf was defined as the area under the concentration-time curve from time 0 to infinity. Early enrolling participants (approximately the first 8 adult and first 4 adolescent participants) randomized to ruxolitinib arm followed an "extensive PK" sampling schedule. Subsequent participants randomized to ruxolitinib, any randomized participants receiving ruxolitinib after Cycle 6, and any randomized participants receiving BAT that cross over to ruxolitinib followed the "sparse PK" sampling schedule.
| ng*hour/mL | Ruxolitinib |
|---|---|
| Day 1 | 642 ± 32.7 |
CL/F was defined as the oral dose clearance of ruxolitinib. Early enrolling participants (approximately the first 8 adult and first 4 adolescent participants) randomized to ruxolitinib arm followed an "extensive PK" sampling schedule. Subsequent participants randomized to ruxolitinib, any randomized participants receiving ruxolitinib after Cycle 6, and any randomized participants receiving BAT that cross over to ruxolitinib followed the "sparse PK" sampling schedule.
| Liters/hour | Ruxolitinib |
|---|---|
| Day 1 | 15.6 ± 32.7 |
| Day 15 | 15.2 ± 20.4 |
Vz/F was defined as the apparent oral dose volume of distribution of ruxolitinib. Early enrolling participants (approximately the first 8 adult and first 4 adolescent participants) randomized to ruxolitinib arm followed an "extensive PK" sampling schedule. Subsequent participants randomized to ruxolitinib, any randomized participants receiving ruxolitinib after Cycle 6, and any randomized participants receiving BAT that cross over to ruxolitinib followed the "sparse PK" sampling schedule.
| Liters | Ruxolitinib |
|---|---|
| Day 1 | 54.0 ± 25.0 |
| Day 15 | 50.9 ± 33.9 |
tmax was defined as the time to reach the maximum plasma concentration of ruxolitinib. Early enrolling participants (approximately the first 8 adult and first 4 adolescent participants) randomized to ruxolitinib arm followed an "extensive PK" sampling schedule. Subsequent participants randomized to ruxolitinib, any randomized participants receiving ruxolitinib after Cycle 6, and any randomized participants receiving BAT that cross over to ruxolitinib followed the "sparse PK" sampling schedule.
| hours | Ruxolitinib |
|---|---|
| Day 1 | 0.833 (0.417 to 4.08) |
| Day 15 | 1.00 (0.417 to 2.00) |
t1/2 was defined as the apparent terminal phase disposition half-life of ruxolitinib. Early enrolling participants (approximately the first 8 adult and first 4 adolescent participants) randomized to ruxolitinib arm followed an "extensive PK" sampling schedule. Subsequent participants randomized to ruxolitinib, any randomized participants receiving ruxolitinib after Cycle 6, and any randomized participants receiving BAT that cross over to ruxolitinib followed the "sparse PK" sampling schedule.
| hours | Ruxolitinib |
|---|---|
| Day 1 | 2.40 ± 28.9 |
| Day 15 | 2.32 ± 19.8 |
The percentage of participants with at least one submission to healthcare encounter was assessed.
| percentage of participants | Ruxolitinib | Best Available Therapy |
|---|---|---|
| Utilization of Medical Resources | 57.0 | 65.8 |
Collected over from Baseline to LPLV (approximately 5 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ruxolitinib | 37/165 (22.4%) | 86/165 (52.1%) | 158/165 (95.8%) |
| Best Available Therapy | 40/158 (25.3%) | 71/158 (44.9%) | 132/158 (83.5%) |
| Ruxolitinib Cross-Over Period | 10/70 (14.3%) | 27/70 (38.6%) | 62/70 (88.6%) |
| Event | Ruxolitinib | Best Available Therapy | Ruxolitinib Cross-Over Period |
|---|---|---|---|
| PneumoniaInfections and infestations | 24/165 | 18/158 | 5/70 |
| PyrexiaGeneral disorders | 11/165 | 7/158 | 3/70 |
| AnaemiaBlood and lymphatic system disorders | 1/165 | 0/158 | 3/70 |
| Respiratory tract infectionInfections and infestations | 2/165 | 0/158 | 3/70 |
| Lower respiratory tract infectionInfections and infestations | 5/165 | 1/158 | 1/70 |
| Ulcerative keratitisEye disorders | 0/165 | 0/158 | 2/70 |
| Upper respiratory tract infectionInfections and infestations | 1/165 | 2/158 | 2/70 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 3/165 | 3/158 | 2/70 |
| Bronchopulmonary aspergillosisInfections and infestations | 3/165 | 4/158 | 0/70 |
| Septic shockInfections and infestations | 2/165 | 4/158 | 1/70 |
| Event | Ruxolitinib | Best Available Therapy | Ruxolitinib Cross-Over Period |
|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 56/165 | 25/158 | 15/70 |
| PyrexiaGeneral disorders | 34/165 | 16/158 | 9/70 |
| HypertensionVascular disorders | 33/165 | 21/158 | 7/70 |
| Alanine aminotransferase increasedInvestigations | 32/165 | 8/158 | 5/70 |
| Blood creatinine increasedInvestigations | 29/165 | 8/158 | 4/70 |
| Upper respiratory tract infectionInfections and infestations | 19/165 | 15/158 | 12/70 |
| CoughRespiratory, thoracic and mediastinal disorders | 25/165 | 15/158 | 12/70 |
| DiarrhoeaGastrointestinal disorders | 27/165 | 23/158 | 6/70 |
| NeutropeniaBlood and lymphatic system disorders | 25/165 | 8/158 | 8/70 |
| FatigueGeneral disorders | 25/165 | 15/158 | 7/70 |
| Age, Continuous(Years) | Ruxolitinib | Best Available Therapy | Total |
|---|---|---|---|
| Mean | 45.9 ± 15.68 | 47.2 ± 16.17 | 46.5 ± 15.92 |
| Sex: Female, Male(Participants) | Ruxolitinib | Best Available Therapy | Total |
|---|---|---|---|
| Female | 56 | 72 | 128 |
| Male | 109 | 92 | 201 |
| Race/Ethnicity, Customized(Participants) | Ruxolitinib | Best Available Therapy | Total |
|---|---|---|---|
| White | 116 | 132 | 248 |
| Black or African American | 2 | 0 | 2 |
| Asian | 33 | 21 | 54 |
| American Indian or Alaska Native | 2 | 0 | 2 |
| Other | 9 | 4 | 13 |
| Unknown | 3 | 7 | 10 |
| Race/Ethnicity, Customized(Participants) | Ruxolitinib | Best Available Therapy | Total |
|---|---|---|---|
| Hispanic/Latino | 13 | 13 | 26 |
| Not Hispanic/Latino | 118 | 115 | 233 |
| Not Reported | 26 | 25 | 51 |
| Unknown | 8 | 11 | 19 |
| ECOG Performance Status(Participants) | Ruxolitinib | Best Available Therapy | Total |
|---|---|---|---|
| 0 | 39 | 42 | 81 |
| 1 | 92 | 82 | 174 |
| 2 | 22 | 22 | 44 |
| 3 | 0 | 2 | 2 |
| Missing | 12 | 16 | 28 |
Showing the first 100 of 191 sites across 31 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2017 to primary completion in May 2020, 34 months.
Results were first posted in Apr 2022, 1 year 11 months after primary completion. A results delay was requested in May 2021.
Of 31 phase 3 interventional studies under Graft vs Host Disease, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 48. This study's 34 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ruxolitinib